Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 18

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 18
---
 governance committee, each of which operates pursuant to a written charter adopted by our board of directors. Our board of directors may also establish other committees from time to time to assist the board of directors. The composition and functioning of all of our committees comply with all applicable requirements of the Sarbanes-Oxley Act, Nasdaq and Securities and Exchange Commission (“SEC”) rules and regulations, subject to applicable phase-in periods for committees. Each committee has a charter, which is available on our website at www.adaptivebiotech.com.**

<div align='center'>12</div>

Independence and Current Committee Positions Our board of directors has determined that all members of our board of directors, except Chad Robins, are independent directors for purposes of the rules of Nasdaq and the SEC. In making this determination, our board of directors considered the relationships that each non-employeedirector has with us and all other facts and circumstances that our board of directors deemed relevant, including the beneficial ownership of our common stock by each non-employeedirector. The composition and functioning of our board of directors and each of our committees complies with all applicable requirements of Nasdaq and the rules and regulations of the SEC. The composition of our board committees and independence of their members are summarized below:

| Name                      |     | Independent |     | Audit Committee |     | Compensation and        
 Human Capital Committee |     | Nominating and 
 Corporate      
 Governance     
 Committee      |
| Michelle Griffin          |     | Yes         |     | Member (Chair)  |     |                         |     |                |
| Robert Hershberg, PhD, MD |     | Yes         |     |                 |     | Member (Chair)          |     |                |
| Peter Neupert(1)          |     | Yes         |     | Member          |     | Member                  |     | Member (Chair) |
| Katey Owen, PhD           |     | Yes         |     |                 |     | Member                  |     |                |
| Michael Pellini, MD(2)    |     | Yes         |     | Member          |     |                         |     | Member         |
| Chad Robins               |     | No          |     |                 |     |                         |     |                |

| (1) | Lead Independent Director |

| (2) | Dr. Pellini’s term as a Class III director is expiring at our 2025 Annual Meeting, and Dr. Pellini is not being nominated for reelection. |

Audit Committee Service and